ストックスクリーナーアプリを入手
187.03
1.43%
-2.72
前日終値:
$189.75
開ける：
$188.22
24時間の取引高:
2.12M
Relative Volume:
1.11
時価総額：
$290.06B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
56.17
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
+3.00%
1か月 パフォーマンス:
-3.99%
6か月 パフォーマンス:
+105.53%
1年 パフォーマンス:
+167.38%
1日の値動き範囲:
$186.44
$189.08
1週間の範囲:
$182.67
$191.50
52週間の値動き範囲:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca PLC stock (US6549022043): insider sale and oncology spotlight draw investor attention - AD HOC NEWS
Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC - GuruFocus
AstraZeneca (AZN) officer Sharma Mani sells 11,893 Ordinary Shares in open market - Stock Titan
FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress - Yahoo Finance UK
EU regulator backs approval for AstraZeneca's experimental breast cancer pill - Reuters
AstraZeneca and Daiichi cancer drugs clear regulatory hurdles - London South East
AstraZeneca PLC stock (US6549022043): oncology growth and new approvals keep investors watching - AD HOC NEWS
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates - AstraZeneca
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours - AstraZeneca
CT UK Capital underperforms as underweight on AstraZeneca, Shell - marketscreener.com
AstraZeneca plc stock (GB0009895292): Deutsche Bank reiterates Sell despite strong analyst consensus - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca plc stock (GB0009895292): Deutsche Bank reiterates Sell rating as pipeline and US listin - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert - AD HOC NEWS
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca stock holds steady after net debt rises £2.5 billion following dividend payment - Traders Union
Research Alert: CFRA Adds Shares Of Astrazeneca Plc To The Total Return Portfolio - 富途牛牛
How VEPPANU Approval Frames Expectations For AstraZeneca’s Camizestrant In ESR1 Disease - Yahoo Finance
AstraZeneca plc stock (GB0009895292): Latest catalyst after recent company news - AD HOC NEWS
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
AstraZeneca PLC stock (US6549022043): US drug approvals keep Big Pharma name in focus - AD HOC NEWS
AZN Stock Price and Chart — LSE:AZN - TradingView
AstraZeneca’s Earnings Call Balances Growth and Risk - TipRanks
AstraZeneca plc stock (GB0009895292): oncology momentum and new data keep investors watching - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): US drug approvals keep pharma giant in focus - AD HOC NEWS
AstraZeneca stock (GB0009895292): lung cancer data and Q1 update keep focus on oncology pipeline - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): US drug approvals and oncology milestone keep pipeline in focu - AD HOC NEWS
FDA approves AstraZeneca’s new kind of hypertension drug - BioPharma Dive
Flat trading for AstraZeneca stock as GBX13,902 resistance keeps gains in check - Traders Union
AZN News | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
AstraZeneca plc stock (GB0009895292): US drug approvals trigger milestone payment and fresh attentio - AD HOC NEWS
AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation - Yahoo Finance
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology PortfoliosAstraZeneca (NYSE:AZN) - Benzinga
New hypertension option as Astrazeneca’s Baxfendy wins FDA nod - BioWorld News
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy - Yahoo! Finance Canada
AstraZeneca CEO Pascal Soriot receives vested share award under performance plan - Investing.com
AstraZeneca (AZN) CEO granted 18,359 shares as performance award vests - Stock Titan
AstraZeneca receives US approval for Baxfendy to treat hypertension By Investing.com - Investing.com Nigeria
AstraZeneca receives US approval for Baxfendy to treat hypertension - Investing.com
AstraZeneca plc stock (GB0009895292): oncology and vaccines stay in focus after latest earnings and - AD HOC NEWS
AstraZeneca (AZN) secures US approval for first-in-class Baxfendy hypertension treatment - Stock Titan
Enhertu gains early breast cancer approvals for AstraZeneca (NYSE: AZN) in US - Stock Titan
The Zacks Analyst Blog Highlights Costco, Coca-Cola, AstraZeneca and Franklin Financial Services - Yahoo Finance
Citi sees buying opportunity at AstraZeneca after recent falls - Sharecast.com
New AstraZeneca drug targets hormone behind stubborn high blood pressure - Stock Titan
AstraZeneca wins US FDA approval for hypertension drug Baxfendy - MSN
AstraZeneca Announce Baxfendy Approval in the US May 18, 2026 - James Sharp & Co.
US regulator greenlights AstraZeneca's blood pressure drug Baxfendy - London South East
AstraZeneca secures US approval for two drugs - Sharecast.com
AstraZeneca stock holds steady as Enhertu FDA approval for early breast cancer balances sentiment - Traders Union
AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu - Proactive financial news
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
大文字化:
|
ボリューム (24 時間):